Navjot Rakkar, MD
Internal Medicine · Surprise, AZNPI 1598714263
Payments from drug & device makers
Across 104 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$380
- Novo Nordisk$181
- AbbVie$163
- Philips North America LLC$151
- GSK$115
- Lilly USA, LLC$92
- plus $694 from 19 others
What the payments were for
- Food & beverage$1,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $380 |
| Novo Nordisk | 11 | $181 |
| AbbVie(2 entities) | 9 | $163 |
| Philips North America LLC | 7 | $151 |
| GSK | 5 | $115 |
| Lilly USA, LLC | 6 | $92 |
| Boehringer Ingelheim | 5 | $87 |
| Pfizer | 3 | $81 |
| Abbott | 4 | $79 |
| Amgen | 5 | $73 |
| Amarin Pharma, Inc. | 3 | $45 |
| Johnson & Johnson | 3 | $44 |
| Eisai Inc. | 2 | $37 |
| Boston Scientific | 2 | $34 |
| Novartis | 2 | $32 |
| Medtronic | 2 | $26 |
| Exact Sciences | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Biotronik NRO, Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,776 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $119,550 |
| MounjaroTirzepatide | 80 | $103,926 |
| JardianceEmpagliflozin | 59 | $85,222 |
| OzempicSemaglutide | 63 | $60,654 |
| JanuviaSitagliptin Phosphate | 50 | $56,702 |
| FarxigaDapagliflozin Propanediol | 43 | $47,609 |
| XareltoRivaroxaban | 37 | $33,549 |
| RybelsusSemaglutide | 12 | $29,072 |
| MyrbetriqMirabegron | 33 | $23,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $16,856 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $16,824 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,698 |
| BelsomraSuvorexant | 22 | $10,407 |
| Levothyroxine Sodium | 694 | $7,120 |
| MotegrityPrucalopride Succinate | 12 | $6,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $81 | $123,611135 claims |
| Lilly USA, LLCMounjaro | $92 | $103,92680 claims |
| Novo NordiskOzempic, Rybelsus | $181 | $89,72775 claims |
| Boehringer IngelheimJardiance | $87 | $85,22259 claims |
| MerckJanuvia, Belsomra | $13 | $67,10972 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $380 | $63,30767 claims |
| Johnson & JohnsonXarelto | $44 | $33,54937 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $115 | $20,49225 claims |
| AbbVieSynthroid | $163 | $2,39140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Surprise
- Quang VoSurprise$678K
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.